HMGB2 Release Promotes Pulmonary Hypertension and Predicts Severity and Mortality of Patients With Pulmonary Arterial Hypertension.
Deping KongJing LiuJunmi LuCheng ZengHao ChenZhenzhen DuanKe YuXialei ZhengPu ZouLiufang ZhouYicheng LvQingye ZengLin LuJiang LiYuhu HePublished in: Arteriosclerosis, thrombosis, and vascular biology (2024)
Our findings indicate that targeting HMGB2 might be a novel therapeutic strategy for treating PH. Serum HMGB2 levels could serve as a novel biomarker for diagnosing PA hypertension and determining its prognosis.